SARDA PROTEINS LTD. (SRDAPRT) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of SARDA PROTEINS LTD. stock ₹10.66, price ₹123, that is 91.3% below the price, quality 34 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range ₹0.0002 – ₹316.60 · fair‑value band ₹9.60 – ₹11.60 · the ₹122.50 price screens above the ₹10.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow SARDA PROTEINS in your weekly email
Every Wednesday you see whether SARDA PROTEINS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sarda Proteins Ltd trades in edible oils and agri commodities in India. It is involved in trading mustard oil and mustard oil cake, as well as soya refined oil; and agricultural commodities, such as oil seeds, grains, and edible oils. The company also provides manpower services.
Show moreShow less
Sarda Proteins Ltd was incorporated in 1991 and is based in Jaipur, India.
Stock analysis
SARDA PROTEINS LTD. (SRDAPRT) currently trades at ₹122.50, while our model-based Fair Value estimate is ₹10.66, 91% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹93.49 per share, and 1 of the 12 models we run sit above the ₹122.50 price.
Bear case: the Earnings-Based group reads lowest at ₹4.21, and 11 of the 12 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹9.60 (bear) to ₹11.60 (bull), the price of ₹122.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
SARDA PROTEINS LTD. reported revenue of ₹162M in FY2026 versus ₹108M in FY2022, a compound +10.7%/yr. Reported net income was ₹4.5M in FY2026, compounding +10.3%/yr from FY2022.
Key figures
Market cap ₹1.2B (≈ $13.0M) Micro · P/E ratio 14.6 · P/S ratio 2.38 · EPS (TTM) ₹8.41 · Net margin 15.3% · Return on equity 23.7% · Return on assets (EBIT) 0.0% · Operating margin −25.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (medium confidence).
What moves the price
The share trades about 26% below its 52-week high and 94% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −2% fair-value upside, at −91%, SRDAPRT screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹4.21 to ₹528.24). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear₹9.60Fair Value ₹10.66Bull₹11.60
Price ₹122.50 · Downside -91.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹5.05 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV₹10.20₹10.42₹10.6071
ROIC Compounder₹10.20₹10.42₹10.6070
Residual Income₹50.04₹54.08₹59.0768
All 12 models by family
Earnings-Based
Graham-Dodd₹3.44₹4.21₹4.7365
EPV₹10.20₹10.42₹10.6071
Multiples
P/E Multiple₹7.97₹10.63₹13.2963
P/S Multiple₹6.45₹8.61₹10.7658
P/B Multiple₹396.18₹528.24₹660.3055
EV/EBIT₹12.46₹13.82₹15.1866
EV/EBITDA₹11.54₹12.59₹13.6567
EV/Revenue₹11.29₹12.54₹13.7954
Asset-Based
NCAV (Graham)₹61.70₹93.49₹116.8654
Economic Profit
Residual Income₹50.04₹54.08₹59.0768
ROIC Compounder₹10.20₹10.42₹10.6070
Growth Earnings
Growth-Adj P/E₹5.63₹8.04₹10.4665
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.60/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ −24.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−24.2%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 2%
⚠ Rate on operating basis: 2026 sits 613% above its own trend.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 627 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside−91.3% · Bottom 25%
Profitability
Return on equity (12 months)23.7% · Top 25%
Return on assets0.5% · Bottom 25%
Net margin (12 months)15.3% · Top 25%
Operating margin (12 months)−25.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)18.6% · Top 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
P/E (12 months)14.6× · Cheaper than median
P/B1.42× · Pricier than median
P/S (12 months)6.75× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 34
FUTURE (revenue growth)93· sector 24
PAST (return on equity)95· sector 31
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 55
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is SARDA PROTEINS LTD. (SRDAPRT) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of ₹10.66 versus a price of ₹122.50, about 91% lower (overvalued).
What is the fair value of SRDAPRT?
Our model-based fair value for SARDA PROTEINS LTD. is ₹10.66 (as of Nov 4, 2026), built from audited fundamentals. The current price: ₹122.50.
What is the quality score of SRDAPRT?
SARDA PROTEINS LTD. has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SARDA PROTEINS LTD. (SRDAPRT)?
Our model-based price target is the fair value of ₹10.66 (as of Nov 4, 2026) from 12 valuation models. Cautious scenario ₹9.60, optimistic scenario ₹11.60. It is a calculation from audited fundamentals, not an analyst target.
What is the SARDA PROTEINS LTD. stock forecast for 2026?
Our models put fair value at ₹10.66, about 91% lower versus a price of ₹122.50 (overvalued). Cautious scenario ₹9.60, optimistic scenario ₹11.60. The calculation is refreshed regularly with new filings.
What is the revenue of SARDA PROTEINS LTD. (SRDAPRT)?
SARDA PROTEINS LTD. reported trailing-twelve-month revenue of about ₹182M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of SARDA PROTEINS LTD. (SRDAPRT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SARDA PROTEINS LTD. it is ₹10.66 per share (as of Nov 4, 2026), against a price of ₹122.50. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is SARDA PROTEINS LTD. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, SRDAPRT trades above its calculated fair value: price ₹122.50, fair value ₹10.66, a gap of about −91% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SRDAPRT?
No. The price is what the market pays today (₹122.50); the fair value is what the company's own numbers justify (₹10.66). For SARDA PROTEINS LTD. the two are ₹111.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is SARDA PROTEINS LTD. worth?
The market values SARDA PROTEINS LTD. at about ₹1.2B (market capitalisation, as of Nov 4, 2026). Per share that is ₹122.50; our models calculate a fair value of ₹10.66 per share.
What do the bullish and bearish scenarios say about SRDAPRT?
Our models span a range for SARDA PROTEINS LTD.: cautious scenario ₹9.60, base ₹10.66, optimistic ₹11.60 per share (as of Nov 4, 2026, price ₹122.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SRDAPRT?
SARDA PROTEINS LTD. trades at a price-to-earnings ratio of 14.6 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹10.66 is built from several models across several years. Other multiples: P/B 1.4, P/S 6.8.
How solid is the balance sheet of SARDA PROTEINS LTD. (SRDAPRT)?
Balance-sheet figures for SARDA PROTEINS LTD. (as of Nov 4, 2026): return on equity 23.7%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is SRDAPRT from its 52-week high?
SARDA PROTEINS LTD. trades at ₹122.50, about 26% below its 52-week high of ₹166.34 and 94% above the low of ₹63.06 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of ₹10.66 is for.
Which stocks are comparable to SARDA PROTEINS LTD.?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SARDA PROTEINS LTD. stock attractive at the current price?
The data as of Nov 4, 2026: price ₹122.50, calculated fair value ₹10.66 (−91%), Quality Score 34/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SRDAPRT calculated?
We run SARDA PROTEINS LTD. through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹10.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0% above its aggregate fair value. SARDA PROTEINS LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SARDA PROTEINS LTD. (SRDAPRT)?
The closing price on Nov 4, 2026 was ₹122.50. Our model-based fair value is ₹10.66, about 91% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SARDA PROTEINS LTD. right now?
The price sits above even our optimistic bull case (₹11.60). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of SARDA PROTEINS LTD.
How large is the market capitalisation of SARDA PROTEINS LTD. (SRDAPRT)?
The market capitalisation of SARDA PROTEINS LTD. is ₹1.2B (≈ $13.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SARDA PROTEINS LTD. (SRDAPRT)?
The price-to-sales ratio of SARDA PROTEINS LTD. is 2.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SARDA PROTEINS LTD. (SRDAPRT)?
Earnings per share at SARDA PROTEINS LTD. are ₹8.41 (price ÷ EPS = P/E 14.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SARDA PROTEINS LTD. (SRDAPRT)?
The net margin of SARDA PROTEINS LTD. is 15.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SARDA PROTEINS LTD. (SRDAPRT)?
The return on equity (ROE) of SARDA PROTEINS LTD. is 23.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SARDA PROTEINS LTD. (SRDAPRT)?
On an EBIT basis the return on assets of SARDA PROTEINS LTD. is 0.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SARDA PROTEINS LTD. (SRDAPRT)?
The operating margin of SARDA PROTEINS LTD. is −25.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SARDA PROTEINS LTD. (SRDAPRT)?
Revenue at SARDA PROTEINS LTD. is growing +18.6% versus a year earlier (3y avg +40.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SARDA PROTEINS LTD. (SRDAPRT)?
Earnings per share at SARDA PROTEINS LTD. are growing +284% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does SARDA PROTEINS LTD. (SRDAPRT) generate?
The free cash flow of SARDA PROTEINS LTD. is −₹764M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch SARDA PROTEINS LTD. in the live analysis
One click puts SARDA PROTEINS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026